Skip to main content
UK Government Updates Regulatory Affairs NewsletterUK Government Updates Regulatory Affairs Newsletter Archive

Eight innovative technologies selected under IDAP pilot phase

By February 14, 2024No Comments

MHRA launched Innovative Devices Access Pathway (IDAP) back in September 2023 to help streamline applications for innovative medical technologies. Today, MHRA have announced that eight innovative medical device technologies are selected for the IDAP. The eight selected innovative devices are:

  • Blood test for Alzheimer’s disease: Roche Diagnostics Ltd has developed an Amyloid Plasma Panel which could help clinicians decide if patients with cognitive impairment should undergo tests or imaging to confirm Alzheimer’s Disease.
  • Use of histotripsy to identify and destroy liver cancer tumours: Developed by Histosonics, focused ultrasound waves, avoid the side-effects seen with other cancer treatments.
  • Portable blood test to triage stroke patients: Developed by Upfront Diagnostics Ltd could help paramedics identify stroke patients more quickly, reducing pressures on emergency departments and improving patient outcomes.
  • AI to determine risk of Chronic Obstructive Pulmonary Disease: Lenus Health Ltd has developed the software which uses data from wearable devices, sensors and apps to predict which patients are at greater risk of hospital admissions.
  • Ear oximeter: EarSwitch Ltd has developed a device which detects oxygen levels from the inner ear-canal, as this area is not pigmented, it could offer better quality readings irrespective of the person’s skin colour compared to standard oximeters.
  • Multiple Sclerosis fatigue app: Avegen Ltd has developed a new smartphone app that delivers exercises, cognitive behaviour therapy and targeted physical activity in a personally customisable format to help patients manage Multiple Sclerosis (MS).
  • Self-test for neutropenia: 52 North Health Ltd has developed a new device to allow chemotherapy patients to self-test at home – using a finger-prick blood test – for neutropenic sepsis. This is a life-threatening condition in patients whose immune system is suppressed.
  • Algorithm infection predictor: Presymptom Health Ltd has developed a new test and algorithm with the potential to predict infection status up to three days before conventional diagnosis of Systemic Inflammatory Response Syndrome (SIRS) is possible.

These selected companies will receive government support of a £10 million funding package to bring their devices to the market. They will also receive tailored regulatory and access support.

This is a part of the government’s long-term plan to ensure the NHS and its patients can get quicker access to new ground-breaking technologies. It is a significant milestone to ensure that these new technologies will help meet the medical needs that are not currently being met.

Next steps: 

The pilot will now enter the next phase. Partners will begin to support the innovators of these technologies to generate the evidence they need for regulatory approval and health-tech assessments, to then support adoption into the NHS.

Tehelj